CORESTEM Inc Market Cap ($30.92 Million)
Market Cap & Net Worth: CORESTEM Inc (166480)
CORESTEM Inc market cap. CORESTEM Inc (KQ:166480) has a market capitalization of $30.92 Million (₩45.63 Billion) as of November 5, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #23470 globally and #1613 in its home market, demonstrating a -2.40% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CORESTEM Inc's stock price ₩1624.00 by its total outstanding shares 28095326 (28.10 Million). Also see 166480 cash flow conversion for how efficiently the company converts equity into cash flow.
CORESTEM Inc Market Cap History (2015–2026)
CORESTEM Inc market cap history from 2015 to 2026. Data shows change from $376.04 Million to $30.92 Million (-20.50% CAGR). Check current stock price of CORESTEM Inc for real-time trading data and today's change.
Index Memberships
CORESTEM Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$207.23 Billion | 0.01% | #812 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$207.23 Billion | 0.01% | #812 of 1384 |
Weight: CORESTEM Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
CORESTEM Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CORESTEM Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 166480 net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
CORESTEM Inc's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $376.04 Million | $18.57 Billion | -$511.72 Million | 0.02x | N/A |
| 2016 | $221.81 Million | $17.95 Billion | -$1.66 Billion | 0.01x | N/A |
| 2017 | $250.37 Million | $18.09 Billion | -$4.01 Billion | 0.01x | N/A |
| 2018 | $228.48 Million | $22.32 Billion | -$3.40 Billion | 0.01x | N/A |
| 2019 | $172.31 Million | $24.28 Billion | -$5.17 Billion | 0.01x | N/A |
| 2020 | $441.72 Million | $26.36 Billion | -$23.19 Billion | 0.02x | N/A |
| 2021 | $352.24 Million | $30.24 Billion | -$7.00 Billion | 0.01x | N/A |
| 2022 | $147.94 Million | $46.29 Billion | -$2.66 Billion | 0.00x | N/A |
| 2023 | $128.90 Million | $33.66 Billion | -$17.67 Billion | 0.00x | N/A |
| 2024 | $73.87 Million | $28.76 Billion | -$26.25 Billion | 0.00x | N/A |
Competitor Companies of 166480 by Market Capitalization
Companies near CORESTEM Inc in the global market cap rankings as of November 5, 2026. Also see total assets of CORESTEM Inc for a full breakdown of the balance sheet.
Key companies related to CORESTEM Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of CORESTEM Inc (2015–2026)
Market capitalization of CORESTEM Inc from 2015 to today. Between 2015 and today, CORESTEM Inc's market cap moved from $376.04 Million to $ 30.92 Million, with a yearly change of -20.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩30.92 Million | -12.12% |
| 2025 | ₩35.19 Million | -52.37% |
| 2024 | ₩73.87 Million | -42.69% |
| 2023 | ₩128.90 Million | -12.87% |
| 2022 | ₩147.94 Million | -58.00% |
| 2021 | ₩352.24 Million | -20.26% |
| 2020 | ₩441.72 Million | +156.35% |
| 2019 | ₩172.31 Million | -24.58% |
| 2018 | ₩228.48 Million | -8.75% |
| 2017 | ₩250.37 Million | +12.88% |
| 2016 | ₩221.81 Million | -41.01% |
| 2015 | ₩376.04 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of CORESTEM Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $30.92 Million USD |
| MoneyControl | $30.92 Million USD |
| MarketWatch | $30.92 Million USD |
| marketcap.company | $30.92 Million USD |
| Reuters | $30.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CORESTEM Inc
CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatm… Read more